


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



INSILICO MEDICINE

**InSilico Medicine Cayman TopCo**

**英矽智能**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3696)**

## **VOLUNTARY ANNOUNCEMENT**

# **INSILICO MEDICINE AND TAIGEN ACHIEVE MILESTONE IN COLLABORATION: OUT-LICENSED CKD ANEMIA CANDIDATE ISM4808 COMPLETES FIRST HUMAN ENROLLMENT AND DOSING IN PHASE I CLINICAL TRIAL**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previously out-licensed to TaiGen Biotechnology (stock code: 4157.TWO) (“**TaiGen**”), has achieved its first milestone. Recently, TaiGen has successfully completed the enrollment and dosing of the first subject in the Phase I clinical trial. The Phase I clinical study is a randomized, double-blind, placebo-controlled trial comprising both single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts, designed to evaluate the safety, tolerability, and pharmacokinetic profile of ISM4808 in healthy adults.

### **About This Collaboration**

In December 2025, Insilico Medicine and TaiGen entered into a licensing agreement for the ISM4808 program. Under the agreement, TaiGen obtained the exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China (including the Chinese mainland, Hong Kong, Macau, and Taiwan). Insilico Medicine is eligible to receive an upfront payment, development and sales-based milestone payments, as well as tiered royalties on net sales, with the total deal value reaching double-digit million dollars.

## **About Insilico Medicine**

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico Medicine is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico Medicine extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit [www.insilico.com](http://www.insilico.com).

## **Forward Looking Statement**

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board  
**InSilico Medicine Cayman TopCo**  
**Mr. Aleksandrs Zavoronkovs, Ph.D.**  
*Chairman, Executive Director, CEO and CBO*

Hong Kong, March 6, 2026

*As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.*